Treatment Interval as a Prognostic Marker in Patients Undergoing Repeated Curative‐Intent Local Treatment for Recurrent Hepatocellular Carcinoma
Hepatology Research · 2026-11 · 56 (11) · 1632-1642
DOI: 10.1111/hepr.70235 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hepatology Research, online erschienen am 01.07.2026. Verfasst von Katsunori Sakamoto und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of Hepato-Biliary-Pancreatic and Transplant Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Die Arbeit nennt 23 Literaturangaben.
Abstract (Originalsprache)
Purpose
This study aimed to investigate the prognostic impact of the interval between curative‐intent local treatments in patients undergoing repeated therapies for recurrent hepatocellular carcinoma after hepatectomy.
Methods
The present retrospective cohort study included 890 patients who underwent hepatectomy for HCC at our hospital between 2001 and 2020. Overall survival (OS) was evaluated from the time of each curative‐intent local treatment, according to the number of treatments received and the intervals between consecutive curative‐intent treatments for intrahepatic recurrence, up to the fourth session.
Results
During follow‐up, 625 patients (65.9%) developed intrahepatic recurrence. The median intervals gradually shortened to 24.9, 14.5, 12.4, and 12.8 months from hepatectomy to the first curative treatment, from the first to the second, from the second to the third, and from the third to the fourth treatments, respectively. For the first and second curative treatments, the pretreatment interval was not an independent predictor of OS. At the third curative treatment, an interval < 18.6 months between the second and third curative treatments independently predicted poorer OS (hazard ratio [HR] 2.280 and 95% confidence interval [CI] 1.046–4.967). For the fourth curative treatment, an interval < 14.1 months between the third and fourth treatments was an independent adverse prognostic factor (HR 4.961, 95% CI 1.607–15.319). The prognostic impact of treatment interval was more pronounced in patients who underwent ≥ 3 treatments, with a significant interaction compared with < 3 treatments.
Conclusions
Among patients who remained eligible for repeated curative‐intent local treatment, a shortened interval between treatments in late‐phase recurrence was an independent predictor of poor prognosis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Division of Hepato-Biliary-Pancreatic and Transplant Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
ORCID-Profile: Katsunori Sakamoto, Satoshi Nomura, Hirofumi Hirao, Takahiro Nishio, Shinya Okumura, Masayuki Okuno, Takashi Ito, Takamichi Ishii, Etsuro Hatano
Zitieren
APA
Sakamoto, K., Yoh, T., Nomura, S., Kadono, K., Kojima, H., Sato, A., Kageyama, S., Hirao, H., Nishio, T., Okumura, S., Ueda, D., Okuno, M., Nishino, H., Yamane, K., Hirata, M., Ogiso, S., Okamoto, T., Nagai, K., Uchida, Y., …, & Hatano, E. (2026). Treatment Interval as a Prognostic Marker in Patients Undergoing Repeated Curative‐Intent Local Treatment for Recurrent Hepatocellular Carcinoma. Hepatology Research, 56(11), 1632-1642. https://doi.org/10.1111/hepr.70235
Vancouver
Sakamoto K, Yoh T, Nomura S, Kadono K, Kojima H, Sato A, et al. Treatment Interval as a Prognostic Marker in Patients Undergoing Repeated Curative‐Intent Local Treatment for Recurrent Hepatocellular Carcinoma. Hepatology Research. 2026;56(11):1632-1642. doi:10.1111/hepr.70235
BibTeX
@article{Sakamoto2026,
author = {Sakamoto, Katsunori and Yoh, Tomoaki and Nomura, Satoshi and Kadono, Kentaro and Kojima, Hidenobu and Sato, Asahi and Kageyama, Shoichi and Hirao, Hirofumi and Nishio, Takahiro and Okumura, Shinya and Ueda, Daisuke and Okuno, Masayuki and Nishino, Hiroto and Yamane, Kei and Hirata, Masaaki and Ogiso, Satoshi and Okamoto, Tatsuya and Nagai, Kazuyuki and Uchida, Yoichiro and Ito, Takashi and Ishii, Takamichi and Hatano, Etsuro},
title = {Treatment Interval as a Prognostic Marker in Patients Undergoing Repeated Curative‐Intent Local Treatment for Recurrent Hepatocellular Carcinoma},
journal = {Hepatology Research},
year = {2026},
volume = {56},
number = {11},
pages = {1632--1642},
doi = {10.1111/hepr.70235}
}
EUVIMED